97191 ⎘
Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
Modified antibody compositions, methods of making and using thereof
#902Anti-NGF compositions and use thereof
#903Methods of preventing or treating pain using anti-NGF antibodies
#904Methods of preventing inflammation and treating pain using anti-NGF compositions
#905Protein belonging to the TNF superfamily involved in signal transduction, nucleic acids encoding same and methods of use thereof
#906NOVEL ANTIBODY FORMULATION
#907Antibodies that immunospecifically bind to B lymphocyte stimulator protein
#908Antibodies against human TWEAK and uses thereof
#909HUMAN ANTIBODIES DERIVED FROM IMMUNIZED XENOMICE
#910Molecular Antigen Array
#911Human antibodies to human RANKL, encoding nucleic acids and methods of treatment
#912Human antibodies to human TNF-like ligand 1A (TL1A)
#913Methods for targeting pulmonary diseases with agents that bind a target in pulmonary tissue
#914Nucleic acids encoding antibodies having altered effector function and methods for making the same
#915STABILIZED FC POLYPEPTIDES WITH REDUCED EFFECTOR FUNCTION AND METHODS OF USE
#916CD86 antagonist multi-target binding proteins
#917Humanized antibodies against LIGHT and uses thereof
#918Antigen binding dimer-complexes, methods of making/avoiding and uses thereof
#919Method for producing antibody using “naked” expression vector expressing type II transmembrane fusion protein
#920Use of TNF-alpha Inhibitors for Treating a Nerve Disorder Mediated by Nucleus Pulposus
#921Methods for treating bone loss with antibodies to OPGL
#922Antibodies against human tweak and uses thereof
#923Modulation of activity of neurotrophins
#924Antagonistic human LIGHT-specific human monoclonal antibodies
#925METHODS FOR TREATING CANCERS AND DISEASES ASSOCIATED WITH 4-1BB (CD137) EXPRESSION
#926Antibody Constant Region Variant
#927Methods of treating aneurysm
#928Humanized anti-CD70 binding agents and uses thereof
#929B LYMPHOCYTE STIMULATOR ASSAYS
#930Methods of treatment using antibodies to Neutrokine-alpha
#931Cells and methods for producing blocking antibodies to human RANKL
#932Single chain multivalent binding proteins with effector function
#933Methods of preventing rejection of transplanted tissue by administering anti-CD40L antibody and dendritic cells loaded with Hsp60sp peptide
#934Self-Buffering Protein Formulations
#935Antagonists of TWEAK and of TWEAK receptor and their use to treat immunological disorders
#936Method of treating lupus nephritis
#937METHODS FOR TREATING TWEAK-RELATED CONDITIONS
#938Methods for treating inflammatory bowel disease
#939TWEAK BINDING ANTIBODIES
#940DUAL VARIABLE DOMAIN IMMUNOGLOBULINS AND USES THEREOF
#941USE OF B LYMPHOCYTE STIMULATOR PROTEIN ANTAGONISTS TO TREAT ASTHMA AND OTHER ALLERGIC AND INFLAMMATORY CONDITIONS OF THE RESPIRATORY SYSTEM
#942Molecular Antigen Array
#943FC FUSION PROTEINS
#944MULTIVALENT AND/OR MULTISPECIFIC RANKL-BINDING CONSTRUCTS
#945ANITIGEN-BINDING CONSTRUCTS
#946ANTIGEN-BINDING CONTRUCTS
#947Detection and treatment of pancreatic, ovarian and other cancers
#948Methods of Treating and/or Preventing Cell Proliferation Disorders with IL-17 Antagonists
#949Prevention of immunological rejection of transplanted stem cells by leukocyte costimulatory molecule blockade
#950ANTIBODIES THAT IMMUNOSPECIFICALLY BIND TO B LYMPHOCYTE STIMULATOR PROTEIN
#951Site-specific attachment of drugs or other agents to engineered antibodies with C-terminal extensions
#952Combination of rocaglamide and apoptosis inducing substances for the treatment of cancer
#953SINGLE CHAIN Fc (ScFc) REGIONS, BINDING POLYPEPTIDES COMPRISING SAME, AND METHODS RELATED THERETO
#954IMMUNOMODULATING TUMOR NECROSIS FACTOR RECEPTOR 25 (TNFR25) AGONISTS, ANTAGONISTS AND IMMUNOTOXINS
#955Remedies for pemphigus containing anti-Fas ligand antibodies
#956Dual variable domain immunoglobulins and uses thereof
#957Kits for detecting rank
#958USE OF CD95 INHIBITORS FOR THE TREATMENT OF INFLAMMATORY DISORDERS
#959Methods and Compositions for Treating Conditions of the Eye
#960SINGLE DOMAIN ANTIBODIES DIRECTED AGAINST TUMOR NECROSIS FACTOR-ALPHA AND USES THEREFOR
#961METHOD OF ADMINISTERING THERAPEUTIC POLYPEPTIDES, AND POLYPEPTIDES THEREFOR
#962Apo-2 Ligand
#963STABILIZED SINGLE DOMAIN ANTIBODIES
#964COMPOSITIONS MONOVALENT FOR CD40L BINDING AND METHODS OF USE
#965METHODS AND COMPOSITIONS FOR PREVENTING RADIATION-INDUCED PNEUMONITIS
#966NEUTROKINE-ALPHA AND NEUTROKINE-ALPHA SPLICE VARIANT
#967Anti-CD70 antibody-drug conjugates and their use for the treatment and prevention of cancer and immune disorders
#968LIGHT inhibitors for asthma, lung and airway inflammation, respiratory, interstitial, pulmonary and fibrotic disease treatment
#969Antibodies against APRIL as biomarkers for early prognosis of lymphoma patients
#970B LYMPHOCYTE STIMULATOR ASSAYS
#971ANTIBODIES THAT IMMUNOSPECIFICALLY BIND TO B LYMPHOCYTE STIMULATOR PROTEIN
#972Viral chemokine-antigen fusion proteins
#973SOLUBLE RECEPTOR BR43X2 AND METHODS OF USING
#974SOLUBLE RECEPTOR BR43X2 AND METHODS OF USING
#975COMPOSITIONS FOR TREATING PSORIASIS
#976Method of inhibiting osteoclast activity
#977Angiotensin peptide-carrier conjugates and uses thereof
#978Anti-OX40L antibodies
#979Human anti-OPGL neutralizing antibodies as selective OPGL pathway inhibitors
#980NEUTROKINE-ALPHA ANTIBODIES AND METHODS OF USE THEREOF
#981Ligands of the Natural Killer (NK) Cell Surface Marker CD27 and Therapeutic Uses Thereof,
#982METHODS OF MODULATING IMMUNE RESPONSES BY MODULATING TIM-1, TIM-2 AND TIM-4 FUNCTION
#983REMEDIES FOR PEMPHIGUS CONTAINING ANTI FAS LIGAND ANTIBODIES
#984TRAIL AND METHODS OF MODULATING T CELL ACTIVITY AND ADAPTIVE IMMUNE RESPONSES USING TRAIL
#985SINGLE-CHAIN MULTIVALENT BINDING PROTEINS WITH EFFECTOR FUNCTION
#986Human immune therapies using a CD27 agonist alone or in combination with other immune modulators
#987SINGLE DOMAIN ANTIBODIES DIRECTED AGAINST TUMOR NECROSIS FACTOR-ALPHA AND USES THEREFOR
#988USE OF B LYMPHOCYTE STIMULATOR PROTEIN ANTAGONISTS TO PROMOTE TRANSPLANTATION TOLERANCE
#989Anti-properdin antibodies
#990Amino acid sequences directed against RANK-L and polypeptides comprising the same for the treatment of bone diseases and disorders
#991METHODS OF TREATMENT USING ANTIBODIES TO NEUTROKINE-ALPHA
#992DNA encoding a soluble fragment of TRAIL polypeptide
#993Neutralization of CD95 activity blocks invasion of glioblastoma cells in vivo
#994PROGNOSTIC METHOD FOR THE DETERMINATION OF THE SUITABILITY OF BIOPHARMACEUTICAL TREATMENT
#995ANTI-OX40L ANTIBODIES AND METHODS USING SAME
#996Method to treat using antagonistic anti-hTNFSF13b human antibodies
#997TREATMENT OF CANCER
#998NEUTROKINE-ALPHA ANTIBODIES AND METHODS OF USE THEREOF
#999NOVEL BONE MASS INCREASING AGENT
#1000Antibodies against human tweak and uses thereof
#1001Treatment of ectodermal dysplasia with EDA1 fusion proteins
#1002LIGAND (ACT-4-L) TO A RECEPTOR ON THE SURFACE OF ACTIVATED CD4+ TCELLS
#1003Ligand
#1004BAFF, inhibitors thereof and their use in the modulation of B-cell response
#1005INDUCTION OF IMMUNE TOLERANCE
#1006Homogeneous Antibody Populations
#1007Human Anti-OPGL Neutralizing Antibodies As Selective OPGL Pathway Inhibitors
#1008Bone microenvironment modulated seizure treatments
#1009Method of screening baff suppressor or inhibitor
#1010NEUTROKINE-ALPHA AND NEUTROKINE-ALPHA SPLICE VARIANT
#1011METHODS OF USING SINGLE NUCLEOTIDE POLYMORPHISMS IN THE TL1A GENE TO PREDICT OR DIAGNOSE INFLAMMATORY BOWEL DISEASE
#1012MODIFIED ANTIBODY COMPOSITIONS, METHODS OF MAKING AND USING THEREOF
#1013ANTI-CD70 ANTIBODY-DRUG CONJUGATES AND THEIR USE FOR THE TREATMENT OF CANCER AND IMMUNE DISORDERS
#1014Anti-OX40L antibodies
#1015Treatment of renal cell carcinoma with anti-CD70 antibody-drug conjugates
#1016Variant target binding agents and uses thereof
#1017HUMAN ANTIBODIES THAT BIND CD70 AND USES THEREOF
#1018NOVEL RECEPTOR FOR CD40L AND USES THEREOF
#1019TREATMENT OF B-CELL CANCERS WITH ANTI-CD70 ANTIBODY-DRUG CONJUGATES
#1020Use of an antibody that blocks TNF-alpha activity for treating a nerve disorder mediated by nucleus pulposus
#1021COMBINATION THERAPY FOR B CELL DISORDERS
#1022Method for making monoclonal antibodies and cross-reactive antibodies obtainable by the method
#1023ANTIBODIES THAT BIND TO OBM
#1024TREATMENT OF PSORIATIC ARTHRITIS WITH ANTI-CD70 ANTIBODY
#1025ANTIBODIES THAT IMMUNOSPECIFICALLY BIND TO B LYMPHOCYTE STIMULATOR
#1026Binding proteins, including antibodies, antibody derivatives and antibody fragments, that specifically bind CD154 and uses thereof
#1027Amino acid sequences directed against RANK-L and polypeptides comprising the same for the treatment of bone diseases and disorders
#1028Pharmaceutical formulation of an antibody against OX40L
#10294-1 bb ligand in inflammatory diseases
#1030Methods of antagonizing binding of CD40 to CD40L with CD40L-specific monovalent polypeptides
#1031CD40L-specific monovalent polypeptides
#1032DcR3 polypeptide, A TNFR homolog
#1033HARMINE COMPOUNDS FOR PROMOTING BONE GROWTH
#1034METHODS FOR TREATING AUTOIMMUNE AND CHRONIC INFLAMMATORY CONDITIONS USING ANTAGONISTS OF CD30 OR CD30L
#1035Method for Cloning Avian-Derived Antibodies
#1036ANTAGONISTS OF TWEAK AND OF TWEAK RECEPTOR AND THEIR USE TO TREAT IMMUNOLOGICAL DISORDERS
#1037COMPOSITION
#1038POLYPEPTIDE CONSTRUCTS FOR SUBLINGUAL ADMINISTRATION
#1039Agents that bind a target in pulmonary tissue for targeting respiratory diseases
#1040Antagonistic human LIGHT-specific human monoclonal antibodies
#1041Polypeptide constructs including VHH directed against EGFR for intracellular delivery
#1042Human antibodies derived from immunized xenomice
#1043Antibodies that immunospecifically bind to B lymphocyte stimulator protein
#1044POLYPEPTIDE CONSTRUCTS FOR TOPICAL ADMINISTRATION
#1045POLYPEPTIDE CONSTRUCTS FOR RECTAL AND/OR VAGINAL ADMINISTRATION
#1046POLYPEPTIDE CONSTRUCTS FOR NASAL ADMINISTRATION
#1047Methods for treating TWEAK-related conditions
#1048Methods of antagonizing the binding of CD40 to CD40L with CD40L-specific monovalent polypeptides in autoimmune individuals
#1049CD 40 Binding Molecules and CTL Pepetides for Treating Tumors
#1050Humanized antibodies against TL1A
#1051Polynucleotides encoding heavy and light chains of antibodies to OPGL
#1052CD30 Ligand
#1053Single-chain Fc (scFc) regions, binding polypeptides comprising same, and methods related thereto
#1054Stabilized single domain antibodies
#1055Anti-CD70 antibody and its use for the treatment and prevention of cancer and immune disorders
#1056Defective ribosomal products in blebs (DRibbles) and methods of use to stimulate an immune response
#1057METHODS OF TARGETING BAFF
#1058METHODS AND COMPOSITIONS FOR PREVENTING RADIATION-INDUCED PNEUMONITIS
#1059Method for high-level secretory production of protein
#1060Apo-2 ligand
#1061METHODS FOR INHIBITING AN IMMUNE RESPONSE BY BLOCKING THE GP39/CD40 AND CTLA4/CD28/B7 PATHWAYS AND COMPOSITIONS FOR USE THEREWITH
#1062Single-Chain Multivalent Binding Proteins with Effector Function
#1063Neutrokine-alpha antibodies and methods of use thereof
#1064Multispecific binding molecules comprising connecting peptides
#1065Antigen Arrays for Treatment of Allergic Eosinophilic Diseases
#1066Human antibodies derived from immunized xenomice
#1067Humanized anti-CD70 binding agents and uses thereof
#1068Methods and compositions for use in treatment of patients with autoantibody positive disease
#1069Canine RANKL and methods for preparing and using the same
#1070Antibody Compositions and Methods
#1071CXCL13 Antagonists and Their Use for the Treatment of Inflammatory Diseases
#1072LIGHT Inhibitors For Asthma, Lung and Airway Inflammation, Respiratory, Interstitial, Pulmonary and Fibrotic Disease Treatment
#1073Use of TRAIL polypeptides to induce apoptosis
#1074BAFF, inhibitors thereof and their use in the modulation of B-cell response and treatment of autoimmune disorders
#1075NEUTROKINE-ALPHA AND NEUTROKINE-ALPHA SPLICE VARIANT
#1076Optimized Fc variants and methods for their generation
#1077ANTIBODY COMPOSITIONS AND METHODS
#1078METHODS AND COMPOSITIONS FOR USE IN TREATMENT OF PATIENTS WITH AUTOANTIBODY POSITIVE DISEASE
#1079METHODS AND COMPOSITIONS FOR USE IN TREATMENT OF PATIENTS WITH AUTOANTIBODY POSITIVE DISEASE
#1080Optimized Fc variants and methods for their generation
#1081Anti-CD70 antibody and its use for the treatment of cancer and immune disorders
#1082Ligand (ACT-4-L) to a Receptor on the Surface of Activated CD4+ T-Cells
#1083Methods of treatment using antibodies to neutrokine-alpha
#1084Optimized Fc variants and methods for their generation
#1085Anti-OX40L antibodies and methods using same
#1086Human monoclonal antibodies to CD70
#1087Single domain antibodies directed against tumour necrosis factor-alpha and uses therefor
#1088Methods for interfering with rank signaling
#1089CHIMERIC PANCREAS
#1090Self-Buffering Protein Formulations
#1091Method of screening Baff suppressor or inhibitor
#1092Anti-CD154 antibodies
#1093Measurement of soluble Tweak levels for evaluation of lupus patients
#1094Methods and Compositions for Modulating Tweak and Fn14 Activity
#1095TREATMENT OF CANCER
#1096Molecular antigen arrary
#1097Methods of evaluating BAFF
#1098Use of Baff to Treat Th2-Mediated Conditions
#1099Therapeutic Strategy for Treating Autoimmune and Degenerative Diseases
#1100Tweak binding antibodies
#1101COMPOSITIONS AND METHODS FOR TREATING INFLAMMATORY LUNG DISEASE
#1102Thalidomide and thalidomide derivatives for treating spinal disorders mediated by nucleus pulposus
#1103Methods for Treating Autoimmune and Chronic Inflammatory Conditions Using Antagonists of CD30 or CD30L
#1104Methods of Using Apo2l Receptor Agonists and Ink Cell Activators
#1105TREATING AND EVALUATING INFLAMMATORY DISORDERS
#1106Compositions and methods for the treatment of immunologic disorders
#1107Antibodies to OCIF-binding molecules
#1108Apo-2 ligand
#1109Method for making monoclonal antibodies and cross-reactive antibodies obtainable by the method
#1110Antagonistic anti-hTNFSF13b human antibodies
#1111Methods and Compositions for Highly Sensitive Detection of Molecules
#1112ANTI-CD70 ANTIBODY AND ITS USE FOR THE TREATMENT OF CANCER AND IMMUNE DISORDERS
#1113Treatment of immune disorders with anti-CD70 antibody
#1114Aglycosyl anti-CD154 (CD40 ligand) antibodies and uses thereof
#1115Antibodies with enhanced antibody-dependent cellular cytotoxicity activity, methods of their production and use
#1116ISOLATION OF ANTIBODIES THAT CROSS-REACT AND NEUTRALIZE RANKL ORIGINATING FROM MULTIPLE SPECIES
#1117Transplant tolerance by costimulation blockade and T-cell activation-induced apoptosis
#1118Method for highly sensitive detection of single protein molecules labeled with fluorescent moieties
#1119Therapeutic applications of T-BAM (CD40L) technology to treat diseases involving smooth muscle cells
#1120ANTI-CD70 ANTIBODY-DRUG CONJUGATES AND THEIR USE FOR THE TREATMENT OF CANCER AND IMMUNE DISORDERS
#1121Specific TNF-A inhibitors for treating spinal disorders mediated by nucleous pulposus
#1122Protein belonging to the TNF superfamily involved in signal transduction, nucleic acids encoding same, and methods of use thereof
#1123Kits for detecting rank nucleic acids
#1124Compositions and methods for treating inflammatory lung disease
#1125CD154 blockade therapy for pancreatic islet tissue transplantation
#1126Anti-CD70 antibody and its use for the treatment and prevention of cancer and immune disorders
#1127TWEAK as a therapeutic target for treating central nervous system diseases associated with cerebral edema and cell death
#1128CD95-Fc fusion proteins
#1129Modulation of activity of neurotrophins
#1130Use of a CD40:CD154 binding interruptor to prevent counter-adaptive immune responses, particularly graft rejection
#1131Single domain antibodies directed against tumour necrosis factor-alpha and uses therefor
#1132Induction of immune tolerance
#1133Treament of lupus nephritis with anti-CD40L compounds
#1134Method for Treating Immune Dysfunction by Regulation of CD40 Ligand Expression
#1135Stabilized single domain antibodies
#1136Methods and compounds for disruption of CD40R/CD40L signaling in the treatment of Alzheimer's disease
#1137Antibodies Against Tumor Necrosis Factor Delta (APRIL)
#1138Altered antibodies having improved antigen-binding affinity
#1139RANKL antibody-PTH/PTHrP chimeric molecules
#1140Immunomodulating tumor necrosis factor receptor 25 (TNFR25) agonists, antagonists and immunotoxins
#1141Antigen arrays for treatment of bone disease
#1142Antagonists of TWEAK and of TWEAK receptor and their use to treat immunological disorders
#1143Use of TNF-alpha inhibitors for treating a nerve disorder mediated by nucleus pulposus
#1144Ligand
#1145Antigen arrays for treatment of allergic eosinophilic diseases
#1146Ligand (ACT-4-L) to a receptor on the surface of activated CD4+ T-cells
#1147Angiotensin peptide-carrier conjugates and uses thereof
#1148Methods and compositions for use in treatment of patients with autoantibody positive disease
#1149Single domain antibodies directed against tumour necrosis factor-alpha and uses therefor
#1150Antibody compositions and methods
#1151Antibodies having altered effector function and methods for making the same
#1152Molecular antigen array
#1153Method for making monoclonal antibodies and cross-reactive antibodies obtainable by the method
#1154Antibodies to OCIF-binding molecules
#1155Immunoregulatory Antibodies and Uses Thereof
#1156COMBINATION THERAPY FOR TREATMENT OF AUTOIMMUNE DISEASES USING B- CELL DEPLETING/IMMUNOREGULATORY ANTIBODY COMBINATION
#1157Soluble receptor BR43x2
#1158Pegylated immunoglobulin variable region polypeptides
#1159Methods for treating autoimmune and chronic inflammatory conditions using antagonists of CD30 or CD30L
#1160COMBINATION THERAPY FOR TREATMENT OF AUTOIMMUNE DISEASES USING B-CELL DEPLETING/IMMUNOREGULATORY ANTIBODY COMBINATION
#1161Methods for treating tweak-related conditions
#1162Inhibition of the CD95 ligand/receptor system for the treatment of neurological disorders and injuries
#1163Anti-cd70 antibody-drug conjugates and their use for the treatment of cancer and immune disorders
#1164TRAIL and methods of modulating T cell activity and adaptive immune responses using TRAIL
#1165Methods for inducing antigen-specific T cell tolerance
#1166Humanized anti-lymphotoxin beta receptor antibodies
#1167Ligand (ACT-4-L) to a receptor on the surface of activated CD4+ T-cells
#1168Methods and compositions for treating conditions of the eye
#1169Methods of treatment using antibodies to Neutrokine-alpha
#1170Methods of Treatment Using Antibodies to Neutrokine-alpha
#1171Aglycosyl anti-CD154 (CD40 ligand) antibodies and uses thereof
#1172Methods of designing and producing novel compounds having improved binding affinity for CD154 or other trimeric proteins
#1173Remedies for pemphigus containing cd40l antogonist as the active ingredient
#1174Protein belonging to the TNF superfamily involved in signal transduction and methods of use thereof
#1175Canine RANKL and methods for preparing and using the same
#1176Treating autoimmune diseases with humanized anti-CD401 antibodies
#1177Humanized antibodies to human GP39, compositions, and therapeutic uses thereof
#1178BLy antagonists and uses thereof
#1179Cytokine designated 4-1BB ligand and human receptor that binds thereto
#1180Camelidae antibodies against imminoglobulin e and use thereof for the treatment of allergic disorders
#1181Cytokine designated 4-1BB ligand and human receptor that binds thereto
#1182Murine monoclonal antibody (5c8) recognizes T-B cell activating molecule (T-BAM) (CD40 LIGAND) on the surface of T-lymphocytes, compositions containing same and methods of use
#1183Ligand
#1184Identification and use of high efficacy vaccine antigens which modulate antigen presenting cells
#1185Expression control using variable intergenic sequences
#1186FAS Ligand Derived Polypeptides
#1187Anti-CD70 antibody and its use for the treatment and prevention of cancer and immune disorders
#1188BAFF, inhibitors thereof and their use in the modulation of B-cell response
#1189Angiotensin peptide-carrier conjugates and uses thereof
#1190Uses of agonists and antagonists to modulate activity of TNF-related molecules
#1191Identification and use of high efficacy vaccine antigens which modulate antigen presenting cells
#1192Ligand
#1193Antibodies that immunospecifically bind to B lymphocyte stimulator protein
#1194Monovalent anti-CD40L antibody polypeptides and compositions thereof
#1195Human antibodies derived from immunized xenomice
#1196Single domain antibodies directed against tumor necrosis factor alpha and uses therefor
#1197FAS ligand derived polypeptides
#1198Anti-CD40CR MR1 antibody
#1199Monoclonal antibodies
#1200Human antibodies derived from immunized xenomice